| P50 | author | Florian Krammer | Q41531975 |
| P2860 | cites work | Avian influenza A H10N8--a virus on the verge? | Q42229269 |
| | Universal influenza virus vaccines: need for clinical trials | Q42248242 |
| | A monoclonal antibody targeting a highly conserved epitope in influenza B neuraminidase provides protection against drug resistant strains. | Q42261275 |
| | Universal anti-neuraminidase antibody inhibiting all influenza A subtypes | Q42264969 |
| | Characterization of three H5N5 and one H5N8 highly pathogenic avian influenza viruses in China | Q42276604 |
| | Novel reassortant influenza A(H5N8) viruses, South Korea, 2014. | Q42593128 |
| | Seroevidence for H5N1 influenza infections in humans: meta-analysis | Q42873008 |
| | Highly pathogenic avian influenza A(H5N8) virus from waterfowl, South Korea, 2014. | Q42920005 |
| | Human infection with Eurasian avian-like influenza A(H1N1) virus, China | Q42931202 |
| | Origin and molecular characteristics of a novel 2013 avian influenza A(H6N1) virus causing human infection in Taiwan. | Q43170681 |
| | Antigenic and genetic characterization of a European avian-like H1N1 swine influenza virus from a boy in China in 2011. | Q43171592 |
| | Human influenza A H5N1 virus related to a highly pathogenic avian influenza virus | Q43209132 |
| | The emergence of H7N9 viruses: a chance to redefine correlates of protection for influenza virus vaccines | Q43673390 |
| | Infection-permissive immunization with influenza virus neuraminidase prevents weight loss in infected mice | Q43705692 |
| | Development of VAX128, a recombinant hemagglutinin (HA) influenza-flagellin fusion vaccine with improved safety and immune response | Q44237462 |
| | Clinical development of a Vero cell culture-derived seasonal influenza vaccine | Q44278166 |
| | Replication of avian influenza viruses in humans | Q44617564 |
| | Purified influenza A virus N2 neuraminidase vaccine is immunogenic and non-toxic in humans | Q44817736 |
| | Cross-reactive and vaccine-induced antibody to an emerging swine-origin variant of influenza A virus subtype H3N2 (H3N2v). | Q45355659 |
| | Preparation of influenza virus subviral particles lacking the HA1 subunit of hemagglutinin: unmasking of cross-reactive HA2 determinants | Q45804843 |
| | The annual production cycle for influenza vaccine | Q47986917 |
| | Universal vaccine based on ectodomain of matrix protein 2 of influenza A: Fc receptors and alveolar macrophages mediate protection. | Q49079509 |
| | Induction of Partial Immunity to Influenza by a Neuraminidase-specific Vaccine | Q54467457 |
| | New world bats harbor diverse influenza A viruses | Q21090482 |
| | Broadly protective monoclonal antibodies against H3 influenza viruses following sequential immunization with different hemagglutinins | Q21131563 |
| | New class of monoclonal antibodies against severe influenza: prophylactic and therapeutic efficacy in ferrets | Q21142658 |
| | Broadly neutralizing hemagglutinin stalk-specific antibodies require FcγR interactions for protection against influenza virus in vivo | Q24568302 |
| | Vaccination with a synthetic peptide from the influenza virus hemagglutinin provides protection against distinct viral subtypes | Q24614628 |
| | A highly conserved neutralizing epitope on group 2 influenza A viruses | Q24630467 |
| | Identification of H2N3 influenza A viruses from swine in the United States | Q24646263 |
| | Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses | Q24649949 |
| | Antibody recognition of a highly conserved influenza virus epitope | Q24655932 |
| | Influenza virus hemagglutinin stalk-based antibodies and vaccines | Q27001190 |
| | A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins | Q27671165 |
| | Highly Conserved Protective Epitopes on Influenza B Viruses | Q27671404 |
| | A common solution to group 2 influenza virus neutralization | Q27680873 |
| | The M segment of the 2009 pandemic influenza virus confers increased neuraminidase activity, filamentous morphology, and efficient contact transmissibility to A/Puerto Rico/8/1934-based reassortant viruses | Q28384333 |
| | Molecular basis for broad neuraminidase immunity: conserved epitopes in seasonal and pandemic H1N1 as well as H5N1 influenza viruses | Q28387782 |
| | An influenza A/H1N1/2009 hemagglutinin vaccine produced in Escherichia coli | Q28750246 |
| | Human infection with a novel avian-origin influenza A (H7N9) virus | Q29620049 |
| | Chimeric hemagglutinin influenza virus vaccine constructs elicit broadly protective stalk-specific antibodies | Q36911722 |
| | Prime-boost interval matters: a randomized phase 1 study to identify the minimum interval necessary to observe the H5 DNA influenza vaccine priming effect | Q36974932 |
| | Hemagglutinin stalk-based universal vaccine constructs protect against group 2 influenza A viruses. | Q37252968 |
| | Highly pathogenic avian influenza A(H7N3) virus in poultry workers, Mexico, 2012. | Q37262363 |
| | Nanoclusters self-assembled from conformation-stabilized influenza M2e as broadly cross-protective influenza vaccines | Q37627859 |
| | Coadministration of seasonal influenza vaccine and MVA-NP+M1 simultaneously achieves potent humoral and cell-mediated responses | Q37690439 |
| | Alternative influenza vaccines made by insect cells | Q37767049 |
| | The future of cell culture-based influenza vaccine production | Q37919896 |
| | An infectious bat-derived chimeric influenza virus harbouring the entry machinery of an influenza A virus | Q41168571 |
| | Avian influenza A(H10N7) virus involvement in mass mortality of harbour seals (Phoca vitulina) in Sweden, March through October 2014. | Q41647946 |
| | Influenza virus A (H10N7) in chickens and poultry abattoir workers, Australia | Q41991090 |
| | Analyzing swine sera for functional antibody titers against influenza A neuraminidase proteins using an enzyme-linked lectin assay (ELLA). | Q42214414 |
| | Induction of broadly reactive anti-hemagglutinin stalk antibodies by an H5N1 vaccine in humans | Q30207889 |
| | Influenza hemagglutinin stem-fragment immunogen elicits broadly neutralizing antibodies and confers heterologous protection | Q30209769 |
| | A cell culture-derived MF59-adjuvanted pandemic A/H7N9 vaccine is immunogenic in adults | Q30210342 |
| | Eliciting broadly protective antibody responses against influenza | Q30217098 |
| | H6 influenza viruses pose a potential threat to human health | Q30217319 |
| | Human infection with avian influenza A H6N1 virus: an epidemiological analysis | Q30217355 |
| | Conserved epitopes of influenza A virus inducing protective immunity and their prospects for universal vaccine development | Q30226873 |
| | Design of an HA2-based Escherichia coli expressed influenza immunogen that protects mice from pathogenic challenge | Q30227081 |
| | The production of hemagglutinin-based virus-like particles in plants: a rapid, efficient and safe response to pandemic influenza | Q30227272 |
| | A phase I clinical trial of a PER.C6 cell grown influenza H7 virus vaccine | Q30228084 |
| | Development of influenza H7N9 virus like particle (VLP) vaccine: homologous A/Anhui/1/2013 (H7N9) protection and heterologous A/chicken/Jalisco/CPA1/2012 (H7N3) cross-protection in vaccinated mice challenged with H7N9 virus. | Q30352405 |
| | Origin and molecular characterization of the human-infecting H6N1 influenza virus in Taiwan | Q30354679 |
| | One-shot vaccination with an insect cell-derived low-dose influenza A H7 virus-like particle preparation protects mice against H7N9 challenge. | Q30355863 |
| | H3 stalk-based chimeric hemagglutinin influenza virus constructs protect mice from H7N9 challenge | Q30356429 |
| | Production and stabilization of the trimeric influenza hemagglutinin stem domain for potentially broadly protective influenza vaccines | Q30356933 |
| | Assessment of influenza virus hemagglutinin stalk-based immunity in ferrets. | Q30357665 |
| | Clinical and epidemiological characteristics of a fatal case of avian influenza A H10N8 virus infection: a descriptive study. | Q30358802 |
| | A live attenuated influenza A(H5N1) vaccine induces long-term immunity in the absence of a primary antibody response. | Q30359896 |
| | Stability of neuraminidase in inactivated influenza vaccines. | Q30360024 |
| | Expansion of genotypic diversity and establishment of 2009 H1N1 pandemic-origin internal genes in pigs in China. | Q30364522 |
| | Induction of broadly cross-reactive antibody responses to the influenza HA stem region following H5N1 vaccination in humans. | Q30366045 |
| | Universal M2 ectodomain-based influenza A vaccines: preclinical and clinical developments. | Q30375991 |
| | Vero cell platform in vaccine production: moving towards cell culture-based viral vaccines. | Q30376550 |
| | Induction of broadly neutralizing H1N1 influenza antibodies by vaccination | Q30391652 |
| | Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection | Q30398435 |
| | A computationally optimized broadly reactive antigen (COBRA) based H5N1 VLP vaccine elicits broadly reactive antibodies in mice and ferrets | Q30399675 |
| | Vaccinate for the next H2N2 pandemic now. | Q30400584 |
| | Why do influenza virus subtypes die out? A hypothesis | Q30406519 |
| | The M segment of the 2009 new pandemic H1N1 influenza virus is critical for its high transmission efficiency in the guinea pig model | Q30406570 |
| | Induction of virus-specific cytotoxic T lymphocytes as a basis for the development of broadly protective influenza vaccines | Q30408295 |
| | Recombinant protein vaccines produced in insect cells | Q30412076 |
| | Hemagglutinin stalk antibodies elicited by the 2009 pandemic influenza virus as a mechanism for the extinction of seasonal H1N1 viruses | Q30412616 |
| | Safety and immunogenicity of multimeric-001--a novel universal influenza vaccine | Q30412800 |
| | The 2009 pandemic H1N1 virus induces anti-neuraminidase (NA) antibodies that cross-react with the NA of H5N1 viruses in ferrets | Q30413023 |
| | A distinct lineage of influenza A virus from bats | Q30413578 |
| | A computationally optimized hemagglutinin virus-like particle vaccine elicits broadly reactive antibodies that protect nonhuman primates from H5N1 infection | Q30414652 |
| | Pandemic H1N1 influenza vaccine induces a recall response in humans that favors broadly cross-reactive memory B cells | Q30417080 |
| | The human potential of a recombinant pandemic influenza vaccine produced in tobacco plants. | Q30417273 |
| | Protection against a lethal H5N1 influenza challenge by intranasal immunization with virus-like particles containing 2009 pandemic H1N1 neuraminidase in mice | Q30418452 |
| | Design of Escherichia coli-expressed stalk domain immunogens of H1N1 hemagglutinin that protect mice from lethal challenge | Q30421687 |
| | Synthetic generation of influenza vaccine viruses for rapid response to pandemics | Q30430578 |
| | Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies | Q30430925 |
| | Role of poultry in the spread of novel H7N9 influenza virus in China | Q33602899 |
| | In the shadow of hemagglutinin: a growing interest in influenza viral neuraminidase and its role as a vaccine antigen | Q33820732 |
| | A universal influenza A vaccine based on the extracellular domain of the M2 protein | Q33875466 |
| | Novel reassortant influenza A(H5N8) viruses in domestic ducks, eastern China | Q33951097 |
| | Influenza virus vaccine based on the conserved hemagglutinin stalk domain | Q34030587 |
| | Highly pathogenic avian influenza virus (H5N8) in domestic poultry and its relationship with migratory birds in South Korea during 2014. | Q34041922 |
| | Receptor specificity of influenza A H3N2 viruses isolated in mammalian cells and embryonated chicken eggs | Q34046062 |
| | An H7N1 influenza virus vaccine induces broadly reactive antibody responses against H7N9 in humans | Q34057737 |
| | Safety and immunogenicity of two different doses of a Vero cell-derived, whole virus clade 2 H5N1 (A/Indonesia/05/2005) influenza vaccine | Q34073541 |
| | Emergence of fatal avian influenza in New England harbor seals | Q34291692 |
| | Antigen-presenting B cells and helper T cells cooperatively mediate intravirionic antigenic competition between influenza A virus surface glycoproteins | Q34350453 |
| | Characterization of a broadly neutralizing monoclonal antibody that targets the fusion domain of group 2 influenza A virus hemagglutinin | Q34594065 |
| | A novel highly pathogenic H5N8 avian influenza virus isolated from a wild duck in China | Q34671712 |
| | Potent CD8+ T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-NP+M1. | Q34699088 |
| | Comparing influenza vaccine efficacy against mismatched and matched strains: a systematic review and meta-analysis | Q34783486 |
| | Identification of an H6N6 swine influenza virus in southern China | Q35013810 |
| | Immunization with purified N1 and N2 influenza virus neuraminidases demonstrates cross-reactivity without antigenic competition | Q35109380 |
| | Complement-dependent lysis of influenza a virus-infected cells by broadly cross-reactive human monoclonal antibodies | Q35599354 |
| | Antibody breadth and protective efficacy are increased by vaccination with computationally optimized hemagglutinin but not with polyvalent hemagglutinin-based H5N1 virus-like particle vaccines | Q35739123 |
| | Influenza viruses expressing chimeric hemagglutinins: globular head and stalk domains derived from different subtypes | Q35943392 |
| | Preliminary assessment of the efficacy of a T-cell-based influenza vaccine, MVA-NP+M1, in humans | Q36014866 |
| | A pan-H1 anti-hemagglutinin monoclonal antibody with potent broad-spectrum efficacy in vivo | Q36023093 |
| | Human infection from avian-like influenza A (H1N1) viruses in pigs, China | Q36037791 |
| | A virus-like particle that elicits cross-reactive antibodies to the conserved stem of influenza virus hemagglutinin. | Q36363177 |
| | Immunity against heterosubtypic influenza virus induced by adenovirus and MVA expressing nucleoprotein and matrix protein-1. | Q36679099 |
| P433 | issue | 5 | |
| P304 | page(s) | 690-701 | |
| P577 | publication date | 2015-03-02 | |
| P1433 | published in | Biotechnology Journal | Q15716480 |
| P1476 | title | Emerging influenza viruses and the prospect of a universal influenza virus vaccine. | |
| P478 | volume | 10 | |